Literature DB >> 25829473

A Brugada syndrome proband with compound heterozygote SCN5A mutations identified from a Chinese family in Singapore.

Boon Yew Tan1, Rita Yu Yin Yong2, Hector Barajas-Martinez3, Robert Dumaine4, Ying Xia Chew5, Pavandip Singh Wasan2, Chi Keong Ching1, Kah Leng Ho1, Linda Seo Hwee Gan5, Nathalie Morin4, Alicia Poh Leng Chong5, Shiao Hui Yap5, Jia Ling Neo5, Eric Peng Huat Yap6, Shabbir Moochhala5, Daniel Thuan Tee Chong1, Weien Chow7, Swee Chong Seow8, Dan Hu9, Mahesh Uttamchandani10, Wee Siong Teo11.   

Abstract

AIMS: Brugada syndrome (BrS) is a rare heritable ventricular arrhythmia. Genetic defects in SCN5A, a gene that encodes the α-subunit of the sodium ion channel Nav1.5, are present in 15-30% of BrS cases. SCN5A remains by far, the highest yielding gene for BrS. We studied a young male who presented with syncope at age 11. This proband was screened for possible disease causing SCN5A mutations. The inheritance pattern was also examined amongst his first-degree family members. METHODS AND
RESULTS: The proband had a baseline electrocardiogram that showed Type 2 BrS changes, which escalated to a characteristic Type I BrS pattern during a treadmill test before polymorphic ventricular tachycardia onset at a cycle length of 250 ms. Mutational analysis across all 29 exons in SCN5A of the proband and first-degree relatives of the family revealed that the proband inherited a compound heterozygote mutation in SCN5A, specifically p.A226V and p.R1629X from each parent. To further elucidate the functional changes arising through these mutations, patch-clamp electrophysiology was performed in TSA201 cells expressing the mutated SCN5A channels. The p.A226V mutation significantly reduced peak sodium current (INa) to 24% of wild type (WT) whereas the p.R1629X mutation abolished the current. To mimic the functional state in our proband, functional expression of the compound variants A226V + R1629X resulted in overall peak INa of only 13% of WT (P < 0.01).
CONCLUSION: Our study is the first to report a SCN5A compound heterozygote in a Singaporean Chinese family. Only the proband carrying both mutations displayed the BrS phenotype, thus providing insights into the expression and penetrance of BrS in an Asian setting. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Brugada syndrome; Channelopathy; Compound heterozygote; Nav1.5; SCN5A

Mesh:

Substances:

Year:  2015        PMID: 25829473     DOI: 10.1093/europace/euv058

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  9 in total

1.  [Functional analysis of a novel SCN5A mutation G1712C identified in Brugada syndrome].

Authors:  Yan-Yu Chen; Shen-Rong Liu; Liang-Zhen Xie; Ting-Yan Zhu; Yi-Zhen Chen; Xiao-Jiang Deng; Su-Rong Meng; Jian Peng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-02-20

Review 2.  Dysfunctional Nav1.5 channels due to SCN5A mutations.

Authors:  Dan Han; Hui Tan; Chaofeng Sun; Guoliang Li
Journal:  Exp Biol Med (Maywood)       Date:  2018-05-27

3.  Distinct Features of Probands With Early Repolarization and Brugada Syndromes Carrying SCN5A Pathogenic Variants.

Authors:  Zhong-He Zhang; Hector Barajas-Martínez; Hao Xia; Bian Li; John A Capra; Jerome Clatot; Gan-Xiao Chen; Xiu Chen; Bo Yang; Hong Jiang; Gary Tse; Yoshiyasu Aizawa; Michael H Gollob; Melvin Scheinman; Charles Antzelevitch; Dan Hu
Journal:  J Am Coll Cardiol       Date:  2021-10-19       Impact factor: 27.203

4.  Switch From Fetal to Adult SCN5A Isoform in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Unmasks the Cellular Phenotype of a Conduction Disease-Causing Mutation.

Authors:  Christiaan C Veerman; Isabella Mengarelli; Elisabeth M Lodder; Georgios Kosmidis; Milena Bellin; Miao Zhang; Sven Dittmann; Kaomei Guan; Arthur A M Wilde; Eric Schulze-Bahr; Boris Greber; Connie R Bezzina; Arie O Verkerk
Journal:  J Am Heart Assoc       Date:  2017-07-24       Impact factor: 5.501

Review 5.  The influence of sodium on pathophysiology of multiple sclerosis.

Authors:  Jacek Zostawa; Jowita Adamczyk; Paweł Sowa; Monika Adamczyk-Sowa
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

6.  Compound Heterozygous SCN5A Mutations in a Toddler - Are they Associated with a More Severe Phenotype?

Authors:  Luciana Sacilotto; Hindalis Ballesteros Epifanio; Francisco Carlos da Costa Darrieux; Fanny Wulkan; Theo Gremen Mimary Oliveira; Denise Tessariol Hachul; Alexandre da Costa Pereira; Mauricio Ibrahim Scanavacca
Journal:  Arq Bras Cardiol       Date:  2017-01       Impact factor: 2.000

7.  Identification of an INa-dependent and Ito-mediated proarrhythmic mechanism in cardiomyocytes derived from pluripotent stem cells of a Brugada syndrome patient.

Authors:  Dongrui Ma; Zhenfeng Liu; Li Jun Loh; Yongxing Zhao; Guang Li; Reginald Liew; Omedul Islam; Jianjun Wu; Ying Ying Chung; Wee Siong Teo; Chi Keong Ching; Boon Yew Tan; Daniel Chong; Kah Leng Ho; Paul Lim; Rita Yu Yin Yong; Brian K Panama; Aaron D Kaplan; Glenna C L Bett; James Ware; Connie R Bezzina; Arie O Verkerk; Stuart A Cook; Randall L Rasmusson; Heming Wei
Journal:  Sci Rep       Date:  2018-07-26       Impact factor: 4.379

8.  Clinical Spectrum of SCN5A Channelopathy in Children with Primary Electrical Disease and Structurally Normal Hearts.

Authors:  Teresa Villarreal-Molina; Gabriela Paola García-Ordóñez; Álvaro E Reyes-Quintero; Mayra Domínguez-Pérez; Leonor Jacobo-Albavera; Santiago Nava; Alessandra Carnevale; Argelia Medeiros-Domingo; Pedro Iturralde
Journal:  Genes (Basel)       Date:  2021-12-22       Impact factor: 4.096

9.  Unique clinical features and long term follow up of survivors of sudden cardiac death in an Asian multicenter study.

Authors:  Pang-Shuo Huang; Jen-Fang Cheng; Wen-Chin Ko; Shu-Hsuan Chang; Tin-Tse Lin; Jien-Jiun Chen; Fu-Chun Chiu; Lian-Yu Lin; Ling-Ping Lai; Jiunn-Lee Lin; Chia-Ti Tsai
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.